Role of Helicobacter pylori infection in extragastroduodenal disorders: Introductory remarks

Journal of Physiology and Pharmacology

Volumn 50, Issue 5, 1999, Pages 683-694

  Konturek, S J ^a   Konturek, P C ^a   Pieniazek P ^a   Bielanski W ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cardiovascular diseases; Cytokines; Cytotoxins; Helicobacter pylori; Immune diseases; Skin diseases

Indexed keywords

AMMONIA; BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; CYTOTOXIN; GAMMA INTERFERON; REACTIVE OXYGEN METABOLITE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; ERADICATION THERAPY; ESOPHAGUS DISEASE; GRAM NEGATIVE INFECTION; GROWTH RETARDATION; HELICOBACTER PYLORI; IMMUNE RESPONSE; IRON DEFICIENCY ANEMIA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; SKIN DISEASE;

ANIMALS; AUTOIMMUNE DISEASES; BILIARY TRACT DISEASES; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LIVER DISEASES; VASCULAR DISEASES;

EID: 0033389395     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Atherton J, Covacci A. Pathogenic properties of Helicobacter pylori. Curr Opin Gastroenterol 1997; 13: Suppl 1: 20-24.
2. Nedrud JG, Czinn SJ. Helicobacter pylori. Curr Opin Gastroenterol 1997; 13: 71-78.
3. Treiber G, Lambert JR. The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol 1998; 93:1080-1084.
4. Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993; 28: 939-942.
5. Treiber G, Lambert JR. The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol 1998; 93:1080-1084.
6. 2-receptors. Aliment Pharmacol Ther 1999; 13: 1669-1674.
7. Konturek P.C, Bielanski W, Konturek S.J. A et al. Role of gastrin in gastric cancerogenesis in Helicobascter pylori infected humans. j Physiol Pharmacol 1999; 50; 5: 857-873.
8. Patel P, Gasbarrini G, Pretolani S, Gasbarrini A, Franceschi F. Extradigestive diseases and Helicobacter pylori infection. Curr Opin Gastroenterol 1997; 13: 52-55.
9. Realdi G, Dore MP, Fastame L. Extradigestive manifestations of Helicobacter pylori infection. Dig Dis Sci 1999; 44: 229-236.
10. Warren JR, Marshall BJ. Unidentified curved Bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-1275.
11. Sternby NH. Atherosclerosis and peptic ulcer. Bull WHO 1976; 53: 571-577.
12. Canino V, Massa F, Bonari L. Osservazioni morfologiche sulle artericgastriche di pazienti affetti da ulcera gastroduodenale. Arch Sci Med Torino 1976; 133 (2): 109-113.
13. Mendall MA, Goggin PM, Molineaus N et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71: 437-439.
14. Pasceri V, Cammarota G, Patti G et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998; 97: 1675-1679.
15. Pienia̧żek P, Karczewska E, Duda A, Tracz W, Konturek SJ. Association of Helicobacter pylori infection with coronary heart disease. J Physiol Pharmacol 1999; 50: 743-751.
16. Patel P, Mendall MA, Carrington D et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311: 711-714.
17. Ponzetto A, La Rovere MT, Sanseverino P, Bazzoli F. Association of Helicobacter pylori infection with coronary heart disease. BMJ 1996; 312: 251.
18. Maier F, Auricchio A, Nilius M, DominguezMunoz JE, Klein H, Malfertheiner P. Lack of association between Helicobacter pylori infection and angiographically documented coronary heart disease. Gut 1996; 2 Suppl: 39: A92.
19. Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M. Prospective relations between Helicobacter pylori infection, coronary heart disease and stroke in middle aged men. Heart 1996; 75: 568-572.
20. Bielański W, Ponka M, Dobrzańska M, Kamiska A. Loster B, Konturek SJ. Extragastric disorders and H. pylori infection. Epidemiological study in Polish urban population. Gut 1999; 45: A87.
21. Gasbarrini A, Sericchio M, Tondi P, Gasbarrini G, Pola P. Association of Helicobacter pylori infection with primary Raynaud phenomenon. Lancet 1996; 348: 966-967.
22. Gasbarrini A, Massari M, Sericchio M et al. Helicobacter pylori and Raynauds phenomenon. Dig Dis Sci 1998; 43: 1641-1645.
23. Gasbarrini A, De Luca A, Fiore G et al. Helicobacter pylori and primary headache. Gastroenterol Int 1977; Suppl 1: 10: 11-13.
24. Kolibásowá K, Cervenková D, Hegyi E, Lengyelová J, Tóth J. Helicobacter pylori: ein moglicher ätiologischer Faktor der chronischen Urticaria. Dermatosen 1994; 42: 235-236.
25. Bohmeyer J, Heller A, Hartig C et al. Assoziation der chronischen Urtikaria mit Helicobacter pylori induzierter Antrum-Gastritis. Hautarzt 1996; 47: 106-108.
26. Tebbe B, Geilen CC, Schulzka JD, Bojarski C, Radenhausen M, Orfanos CE. Helicobacter pylori infection and chronic urticaria. J Am Acad Dermatol 1996; 34: 685-686.
27. Di Campli C, Gasbarrini A, Nucera E et al. Helicobacter pylori infection in idiopathic chronic urticaroa. Gastroenterol Int 1997; 1 Suppl: 10: 48-49.
28. Rebora A, Drago F, Picciotto A. Helicobacter pylori in patients with rosacea. Am J Gastroenterol 1994; 89: 1603-1604.
29. Schneider MA, Skinner RB Jr, Rosenberg EW, Niah IW, Smith L, Zwarum A. Serologic determination of Helicobacter pylori in rosacea patients and controls. Clin Res 1992; 40: 831A.
30. Sharma VK, Lynn A, Kamiski M, Vasudeva R, Howden CW. A study of the prevalence of Helicobacter pylori infection and other markers of upper gastrointestinal tract disease in patients with rosacea. Am J Gastroenterol 1998; 93: 220-222.
31. Kólibasová K, Túthová I, Baumgartner J, Filo V. Eradication of Helicobacter pylori as the only successful treatment in rosacea. Arch Dermatol 1996; 132: 1393.
32. Szlachcic A, Śliwowski Z, Karczewska E, Bielański W, Pytko-Polończyk J, Konturek SJ. Helicobacter pylori (Hp) infection in rosacea. J Physiol Pharmacol 1999; 50: 777-786.
33. Jones MP, Knable AL Jr, White MJ, Darning SJ. Helicobacter pylori in rosacea: lack of association. Arch Dermatol 1998; 134: 511-512.
34. Wedi B, Kapp A. Helicobacter pylori infection and skin diseases. J Physiol Pharmacol 1999; 50: 753-776.
35. Walt RP. Regression of MALT lymphoma and treatment for Helicobacter pylori. Lancet 1996; 348: 1041-1042.
36. Fishbach W, Tacke W, Greiner A, Konrad H, Muller H. Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori. Lancet 1997; 349: 31-32.
37. Matsumoto T, Ida M, Shimizu M. Regression of mucosa associated lymphoidtissue lymphoma of rectum after eradication of Helicobacter pylori. Lancet 1997; 350: 115-116.
38. Faller G, Winter M, Steininger A, Konturek P, Konturek SJ, Kirchner T. Antigastric autoantibodies and gastric secretory function in Helicobacter pylori infected patients with duodenal ulcer and nonulcer dyspepsia. Scand J Gastroenterol 1998; 33: 276-282.
39. Figura N, Guarino E, Gragnoli A et al. Helicobacter pylori infection and thyroid diseases. Gut 1996; 2 Suppl: 39: A93.
40. Figura N, DiCairano G, Lore F. Does Helicobacter pylori infection increase the risk of developing autoimmune thyroid diseases. J Physiol Pharmacol 1999; 50: 817-826.
41. Fox JG, Dewhirst FE, Shen Z et al. Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology 1998; 114: 755-763.
42. Farinati F, De Bona M, Floreani A, Foschia F, Rugge M. Helicobacter pylori and the liver: any relationship. Ital J Gastroenterol Hepatol 1998; 30: 124-128.
43. Nilssen HO, Nilsson I, Castedal M, Lingren S, Olsson R, Wadström T. Helicobacter species in liver and biliary tree diseases. J Physiol Pharmacol 1999; 50: 35.
44. Modlin IM, Sachs G. Acid Related Diseases. Biology and Treatment. Schnetztor Verlag GmbH D-Konstanz 1998; 255-313.
45. Gabryelewicz A, Baniukiewicz A, aszewicz W. Association between H. pylori and gastroesophageal reflux disease (GERD). J Physiol Pharmacol 1999; 50: 2 Suppl: 14-15.
46. Figura N, Perrone F, Rottoli P. Helicobacter pylori infection and alimentary allergy. J Physiol Pharmacol 1999; 50: 2 Suppl: 13-14.
47. Moran AP. Helicobacter pylori, lipopolisaccharide mediated gastric and extragastric pathology. J Physiol Pharmacol 1999; 50: 787-805.
48. Konturek PC, Brzozowski T, Sulekova Z, Meixner H, Hahn EG, Konturek SJ. Enhanced expression of leptin following acute gastric injury in rat. J Physiol Pharmacol 1999; 50: 587-595.
49. Breidert M, Miehle S, Glasow et al. Leptin and its receptor in normal human gastric mucosa and in Helicobacter pylori associated gastritis. J Gastroenterol 1999; 34: 954-961.
50. Brzozowski T, Konturek PC, Moran A et al. Involvement of endogenous leptin in gastroprotection and adaptation to H. pylori lipopolisaccharides. Gastroenterology 2000; 118: in press.
51. Realdi G, Dore MP, Fastome L. Extradigestive manifestations of Helicobacter pylori infection. Facts and fiction. Dig Dis Sci 1999; 44: 229-236.
52. Moss SF. The carcinogenic effects of H. pylori on the gastric epithelial cells J Physiol Pharrmacol 1999; 50: 847-856.
53. Konturek P.C, Bielanski W, et al. Role of gastin in gastric cancerogenesis in Helicobacter pylori infected humans. J Physiol Pharmacol 1999; 50: 857-873.